GlassScriptPhysician profile
Katarzyna E Rela
NPI 1902231558
$2,448.24
in general payments reported to CMS, 2019-2025
32 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $393 · 2023: $1,374 · 2024: $385 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.41 |
| Education | $375.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $209.66 | 2022-2024 | |
| Seagen INC. | $188.27 | 2023 | Padcev, Tivdak, Tukysa |
| Janssen Biotech, INC. | $182.69 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Genentech USA, INC. | $167.74 | 2022-2023 | Polivy, Lunsumio |
| Astellas Pharma US INC | $149.20 | 2023-2024 | Xospata, Padcev |
| Merck Sharp & Dohme LLC | $144.91 | 2022-2024 | Keytruda, Welireg, Lynparza |
| Immunogen, INC. | $141.22 | 2023 | Elahere |
| Incyte Corporation | $138.81 | 2021-2023 | Jakafi |
| Eisai INC. | $131.15 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $116.26 | 2023 | Tagrisso, Calquence |
| Genzyme Corporation | $101.79 | 2023-2024 | |
| Pfizer INC. | $87.93 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $85.73 | 2021-2024 | |
| Celgene Corporation | $66.31 | 2023-2024 | Reblozyl, Pomalyst |
| Exelixis INC. | $63.28 | 2023-2024 | Cabometyx |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $50.51 | 2023 | Clonoseq |
| Lilly USA, LLC | $50.03 | 2022-2023 | Retevmo, Jaypirca |
| Mirati Therapeutics, INC. | $49.15 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $42.72 | 2021-2023 | Tazverik |
| Deciphera Pharmaceuticals INC. | $33.38 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $27.45 | 2021 | |
| Tersera Therapeutics LLC | $22.78 | 2022 | |
| Sobi, INC | $21.21 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.17 | 2024 | Fruzaqla |
| Amgen INC. | $20.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.79 | 2023 | |
| Array Biopharma INC | $20.23 | 2023 | Mektovi, Lorbrena, Braftovi |
| Emd Serono, INC. | $20.00 | 2023 | Bavencio |
| Glaxosmithkline, LLC. | $19.15 | 2023 | Zejula, Jemperli |
| Alnylam Pharmaceuticals INC. | $19.10 | 2023 | Givlaari |
| Jazz Pharmaceuticals INC. | $19.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2024 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katarzyna Rela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.